The outcomes for study participants are similar to the patients who previously received tPA within the 4 hours of witnessed strokes. Patients went to sleep normal and woke up with stroke symptoms which are known as “wake-up strokes”. The research team calls this qDFM for “quantitative DWI FLAIR Mismatch.” With this development, researchers hope to conduct a placebo-controlled trial that will also compare MR with CT imaging for the identification of patients with unwitnessed strokes. They then could safely and effectively be treated with tPA as specified in the press release.
Doctor Lee Schwamm the vice chairman of the Department of Neurology at MGH says “If that phase 3 study is successful, it would lead to a paradigm shift in the way acute stroke patients are treated. Rather than treating based on the number of hours since a stroke began, we can treat based on how much damage the stroke has already caused and how much brain can still be saved. Because the imaging methods we will use in our phase 3 study are available on an MRI or CT scanner in use today, if the results of that trial are positive, the approach could be put into practice immediately.”
International Sales: +1 949-273-8000
Domestic Sales: 1800-400-7972 for US and Canada
Share This Article:
View our Product Catalog Online Here
Ampronix is a renowned authorized master distributor of the medical industry's top brands as well as a world-class manufacturer of innovative technology. Since 1982, Ampronix has been dedicated to meeting the growing needs of the medical community with its extensive product knowledge, outstanding service, and state-of-the-art repair facility. Ampronix prides itself on its ability to offer tailored, one-stop solutions at a faster and more cost-effective rate than other manufacturers. Ampronix is ISO 13485:2003, and ANSI/ESD S20.20-2014 certified.